Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03702049
Other study ID # 20184698
Secondary ID R21MD012696
Status Completed
Phase N/A
First received
Last updated
Start date January 24, 2019
Est. completion date September 4, 2020

Study information

Verified date March 2024
Source University of California, Irvine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tuberculosis (TB) is the prototypical disease of poverty as it disproportionately affects marginalized and impoverished communities. In the US, TB rates are unacceptably high among homeless persons who have a 10-fold increase in TB incidence as compared to the general population. In California, the rate of TB is more than twice the national case rate and recent TB outbreaks have been alarming. Among persons with active TB disease, over 10% die during treatment, with mortality being even higher among homeless persons with TB. While TB can be prevented by treating TB infection (TBI) before it develops into infectious, symptomatic disease, individual factors such as high prevalence of psychosocial comorbidities, unstable housing and limited access to care have led to poor adherence and completion of TBI treatment among homeless persons. Given the complex health disparity factors that affect TBI treatment adherence among homeless persons, this study will assess the feasibility of a theoretically-based novel model of care among persons with TBI and complex chronic illnesses. This study will evaluate an innovative, community-based intervention that addresses critical individual level factors which are potential mechanisms that underlie health disparities in completing TBI treatment among the predominantly minority homeless. The study hypothesis is that improving these conditions, and promoting health by focused screening for TBI, and early detection and treatment for these vulnerable adults will improve TB treatment completion and prevent future TB disease. The proposed theoretically-based health promotion intervention focuses on: 1) completion of TBI treatment, 2) reducing substance use; 3) improving mental health; and 4) improving critical social determinants of TB risk (unstable housing and poor health care access) among homeless adults in the highest TB prevalence area in Los Angeles. A total of 76 homeless adults with TBI will receive this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. This study will determine whether this intervention can achieve higher completion rates than the 65% completion rate among homeless persons reported by previous TB programs.


Description:

Tuberculosis (TB) is a global public health threat, which is driven by social factors, including poverty, inadequate housing, malnutrition, and substance use. In the United States (US), TB disproportionately impacts homeless populations. When compared to the general population, homeless persons have a 10-fold increase in TB incidence. Lack of stable housing and living in congregate settings are predisposing factors for TB Infection (TBI). Homeless persons who develop active TB disease are also at higher risk of death during TB treatment due to mental illness and substance use. Even one TB case among a homeless person can easily lead to widespread TB transmission due to crowded, poorly ventilated, and congregate living situations. Therefore, an extensive public health response is needed for each case of infectious TB disease that develops among homeless persons. Given the significant public health impact of TB among homeless persons, development of effective interventions to prevent TB among homeless persons that are theoretically-based and advance science in the area of best adherence strategies to minimize these health disparities can lead to significant benefits for patients and further reduce the disparity in TB rates between homeless and housed persons. While adherence to traditional TBI treatment with 6 to 9 months of isoniazid (INH) has been dismal, over the last few years, a promising treatment option in form of a 12-dose combination therapy (3HP; rifapentine [RPT] plus isoniazid [INH]), delivered once weekly as directly observed therapy (DOT), has achieved treatment completion rates of 82%. However, homeless populations who are at high risk for TBI have complex, multi-dimensional barriers to TBI treatment adherence. Thus, TBI treatment programs in this population have yielded marginal results of 65% completion to date. Among homeless persons, health disparities are accentuated by additional barriers to TBI treatment adherence, including substance use, mental disorders, and unstable housing. Given the complex factors that affect TBI treatment adherence among homeless persons, the research team developed a theoretically-based novel model of care that has been successfully investigated in other disadvantaged populations. This model involves understanding the behavioral, psychological, and environmental influences on health and developing culturally-tailored interventions to reduce health disparities, and promote health. By engaging nurses, physicians, and community health workers (CHW), the investigators have developed a team-based approach to better understand and support medication adherence by engaging individuals as active partners in managing their own health. This scientific contribution has the potential to be highly significant as new models of care are being proposed to improve timely entry, engagement and retention in care, and supportive services for homeless persons and other vulnerable populations affected by complex health disparities impacting treatment adherence. The pilot study builds on the investigators' extensive three decades of research with homeless persons in improving health, including TBI treatment adherence, HBV vaccination, and adherence to HIV therapy. This study will assess the impact of the TBI program that the investigators have developed, as a single arm intervention study, among 76 eligible TBI homeless adults on completion of 3HP treatment, decrease in drug and alcohol use, improved access to care and mental health, and shelter stability. Completion of 3HP will be compared to a minimum standard completion rate of 65%. This small pilot will generate the effectiveness data for a future R01 application to evaluate the intervention in a definitive randomized-controlled trial (RCT).


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date September 4, 2020
Est. primary completion date May 29, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - self-reported homeless adults (past six months); - age 18 or older; - willing to provide informed consent; - positive for TBI - reported current or recent substance use (past three years) Exclusion Criteria: - screened as having active TB or currently treated for TBI; - history of treatment for active TB or TBI; - a serum aspartate aminotransferase (AST) level of 3-5 times the upper limit of normal; - HIV infected AND receiving antiretroviral therapy (as 3HP is not recommended yet in this group); - not able to speak English or Spanish; - testing pregnant (as 3HP is not recommended in this group); and - judged to be cognitively impaired

Study Design


Intervention

Behavioral:
Nurse-led Community Health Worker TBI (RN/CHW TBI) program
Homeless adults with TBI will be assigned to this program which includes culturally-sensitive education, case management, and directly observed therapy (DOT) delivery of medication among patients who have been prescribed 3HP (12 weeks treatment for latent TB infection) by a medical provider. For this research, 3HP will be delivered to homeless persons infected with TB on a weekly basis by CHW under the guidance of their RN. The RN/CHW team will also provide case management, including health education and referrals for social services.

Locations

Country Name City State
United States Los Angeles Christian Health Centers (LACHC) Los Angeles California
United States Union Rescue Mission Los Angeles California

Sponsors (3)

Lead Sponsor Collaborator
University of California, Irvine National Institute on Minority Health and Health Disparities (NIMHD), University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Completion of TBI Treatment Completion of TBI Treatment will be measured at 3 month follow-up by 90% completion of medication (at least 11/12 doses) consumed over a 12 week period 3 months (12 weeks)
Secondary Drug Use Assessed by the drug items in the Texas Christian University (TCU) Screen V. Yes/No responses to substance dependency questions and the frequency of drug use based on a 5-point scale from 1 (never) to 5 (daily) will be assessed for each drug used. The total score ranges from 0 - 11; corresponding to the number of symptoms endorsed by the participant and the severity of SUD: mild disorder (2-3 points), moderate disorder (4-5 points), or severe disorder (6 or more points). baseline, 3 and 6 months
Secondary Alcohol Use Assessed by the Alcohol items in the Texas Christian University (TCU) Screen V. Problematic use of alcohol was defined as self-identified as being a problem (TCU Item #12) or daily consumption. baseline, 3 and 6 months
Secondary Depression Depression will be assessed by the Center for Epidemiological Studies Short Depression Scale Revised (CESD-R-10) is a 10-item measure for depressive symptoms in the past week (endpoints 0=rarely or none of the time; 3=most of the time). Scale range 0-30, with greater values meaning worse depressive symptoms. Responses are summed. baseline, 3 and 6 months
Secondary Health Care Access Health Care Access will include number of healthcare visits made 3 and 6 months
Secondary Shelter Stability - Days Residing in the Shelter Shelter Factors: Staff will record the type of residence at baseline and follow-up. Shelter Stability will be assessed by the length of time in days residing in the shelter 3 and 6 months
See also
  Status Clinical Trial Phase
Completed NCT04094012 - Risk of SDRs Under 3HP and 1HP Regimen for LTBI Phase 3
Completed NCT01582711 - Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT Phase 3
Recruiting NCT06033807 - Active Screening of Latent Tuberculosis Infection in School Contacts of Active Tuberculosis Patients
Completed NCT01622140 - Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
Completed NCT00557765 - Use of a Gamma-IFN Assay in Contact Tracing for Tuberculosis in a Low-Incidence, High Immigration Area N/A
Completed NCT00463086 - Isoniazid Plus Antiretroviral Therapy to Prevent Tuberculosis in HIV-infected Persons N/A
Active, not recruiting NCT01398618 - Comparing Two Preventive Regimens for Latent Tuberculosis Infection (LTBI) Phase 3
Recruiting NCT00905970 - Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection N/A
Recruiting NCT00449345 - Screening for Latent Tuberculosis in Healthcare Workers With Quantiferon-Gold Assay: A Cost-Effectiveness Analysis N/A
Completed NCT02641106 - VDOT for Monitoring Adherence to LTBI Treatment N/A
Completed NCT00804713 - Screening for Latent Tuberculosis Infection (LTBI) in US Army Recruits N/A
Completed NCT01136161 - Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection Phase 2
Recruiting NCT03312647 - Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection N/A
Completed NCT02810678 - Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment N/A
Completed NCT01223534 - QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study. Phase 4
Withdrawn NCT00558480 - Vitamin A Supplementation for Modulation of Mycobacterium Tuberculosis Immune Responses in Latent Tuberculosis N/A
Recruiting NCT00692809 - Impact of HIV Infection on Latent Tuberculosis (TB) Among Patients With HIV-TB Co-infection N/A
Terminated NCT01761201 - "Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients". Phase 3
Completed NCT01608685 - Interferon Gamma Release Assays (IGRA) Testing Versus Tuberculin Skin Test in Renal Transplant Recipients N/A
Completed NCT01007396 - Diagnosis of Tuberculosis Infection in Health Care Workers Using Ex-vivo Interferon-gamma Assay N/A